Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
662-03-001 ISMRM Abstract

Differentiation of IDH mutant grade 4 astrocytoma from IDH wild type glioblastoma using ITSS volume from SWI-MRI

Primary: Neuro - Tumors
Secondary: Analysis Methods - Classification and Prediction
662-03-001 · Classification: Other Cancer · Thursday, 14 May, 1:40 PM–2:35 PM · Digital Posters Row C
Keywords: IDH mutation SWI Glioblastoma IDH-mutant astrocytoma.
Accepted
Satyajit Maurya1, Sanskriti Srivastava1, Ewunate A Kassaw1, Anup Singh1,2,3
1Centre for Biomedical Engineering, Indian Institute of Technology, Delhi, India
2Yardi School of Artificial Intelligence, Indian Institute of Technology, Delhi, India
3Department of Biomedical Engineering, All India Institute of Medical Sciences, New Delhi, India
Presenting Author: Rupsa Bhattacharjee

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Sengupta, A., Ramaniharan, A. K., Gupta, R. K., Agarwal, S. & Singh, A. Glioma grading using a machine‐learning framework based on optimized features obtained from T1 perfusion MRI and volumes of tumor components. J. Magn. Reson. Imaging 50, 1295–1306 (2019). https://doi.org/10.1002/jmri.26704 [doi]
2. Maurya, S., Kumar Yadav, V., Agarwal, S. & Singh, A. Brain Tumor Segmentation in mpMRI Scans (BraTS-2021) Using Models Based on U-Net Architecture. in International MICCAI Brainlesion Workshop 312–323 (Springer, 2021). https://doi.org/10.1007/978-3-031-09002-8_28 [doi]
3. Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231–1251 (2021). https://doi.org/10.1093/neuonc/noab106 [doi]
4. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009). https://doi.org/10.1056/NEJMoa0808710 [doi]
5. Han, S. et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br. J. Cancer 122, 1580–1589 (2020). https://doi.org/10.1038/s41416-020-0814-x [doi]
6. Kickingereder, P. et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci. Rep. 5, 16238 (2015). https://doi.org/10.1038/srep16238 [doi]
7. Kim, M. et al. Diffusion-and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Eur. Radiol. 30, 2142–2151 (2020). https://doi.org/10.1007/s00330-019-06548-3 [doi]
8. Yadav, V. K. et al. Presence of Fragmented Intratumoral Thrombosed Microvasculature in the Necrotic and Peri‐Necrotic Regions on SWI Differentiates IDH Wild‐Type Glioblastoma From IDH Mutant Grade 4 Astrocytoma. J. Magn. Reson. Imaging. https://doi.org/10.1002/jmri.29695 [doi]
9. Calabrese, E. et al. The University of California San Francisco Preoperative Diffuse Glioma MRI (UCSF-PDGM)(Version 4)[Dataset]. Cancer Imaging Arch. DOI 10, (2022). 10.7937/tcia.bdgf-8v37 [doi]
10. Pezzella, F. & Ribatti, D. Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. Cancer Rep. 5, e1318 (2022). https://doi.org/10.1002/cnr2.1318 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/662-03-001